+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Tyrosine Protein Kinase JAK1 - Pipeline Review, H2 2020

  • ID: 5137242
  • Drug Pipelines
  • July 2020
  • Region: Global
  • 273 pages
  • Global Markets Direct

FEATURED COMPANIES

  • AbbVie Inc
  • AstraZeneca Plc
  • Galapagos NV
  • Impetis Biosciences Ltd
  • Merck & Co Inc
  • Sareum Holdings Plc
  • MORE
Tyrosine Protein Kinase JAK1 - Pipeline Review, H2 2020

Summary

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - JAK1 is a human tyrosine kinase protein essential for signaling for certain type I and type II cytokines. JAK1 plays a critical role in initiating responses to multiple major cytokine receptor families. Expression of JAK1 in cancer cells enables individual cells to contract, potentially allowing them to escape their tumor and metastasize to other parts of the body.

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) pipeline Target constitutes close to 45 molecules. Out of which approximately 44 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 4, 6, 12, 5, 3 and 14 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively.

Report covers products from therapy areas Immunology, Dermatology, Gastrointestinal, Oncology, Musculoskeletal Disorders, Respiratory, Infectious Disease, Central Nervous System, Cardiovascular, Ophthalmology, Hematological Disorders and Women's Health which include indications Rheumatoid Arthritis, Atopic Dermatitis (Atopic Eczema), Alopecia Areata, Psoriasis, Ulcerative Colitis, Crohn's Disease (Regional Enteritis), Systemic Lupus Erythematosus, Coronavirus Disease 2019 (COVID-19), Vitiligo, Ankylosing Spondylitis (Bekhterev's Disease), Graft Versus Host Disease (GVHD), Inflammatory Bowel Disease, Asthma, Diffuse Large B-Cell Lymphoma, Hidradenitis Suppurativa, Inflammation, Multiple Sclerosis, Myelodysplastic Syndrome, Myelofibrosis, Peripheral T-Cell Lymphomas (PTCL), Psoriatic Arthritis, Triple-Negative Breast Cancer (TNBC), Anaplastic Large Cell Lymphoma (ALCL), B-Cell Non-Hodgkin Lymphoma, Bronchiolitis Obliterans, Chronic Lymphocytic Leukemia (CLL), Dermatitis (Eczema), Giant Cell Arteritis (Temporal Arteritis/Cranial Arteritis/Horton Disease), Head And Neck Cancer Squamous Cell Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Lymphoma, Mantle Cell Lymphoma, Non-Small Cell Lung Cancer, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Relapsed Multiple Myeloma, Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia), Thrombocythemia Myelofibrosis, Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), Acute Lung Injury, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Androgenic Alopecia, Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Arthritis, Autoimmune Disorders, B-Cell Chronic Lymphocytic Leukemia, Breast Hyperplasia, Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Chronic Myelomonocytic Leukemia (CMML), Colon Cancer, Colorectal Cancer, Cutaneous Lupus Erythematosus, Cutaneous T-Cell Lymphoma, Cytokine Release Syndrome (Cytokine Storm), Endometrial Cancer, Epstein-Barr Virus (HHV-4) Infections, Essential Thrombocythemia, Follicular Lymphoma, Gastric Cancer, Hairy Cell Leukemia, Hepatocellular Carcinoma, Hypereosinophilic Syndrome, Hypopharyngeal Cancer, Juvenile Arthritis, Kidney Cancer (Renal Cell Cancer), Laryngeal Cancer, Leiomyosarcoma, Lupus Erythematosus, Lupus Nephritis, Marginal Zone B-cell Lymphoma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Prostate Cancer, Multiple Myeloma (Kahler Disease), Myeloproliferative Disorders, Myxoid Liposarcoma, Non-Hodgkin Lymphoma, Oligoarticular Idiopathic Juvenile Arthritis, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Polyarticular Juvenile Idiopathic Arthritis (PJIA), Polycythemia Vera, Polymyalgia Rheumatica (PMR), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Primary Biliary Cholangitis (Primary Biliary Cirrhosis), Primary Myelofibrosis, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Sicca Syndrome (Sjogren), Skin Cancer, Spondyloarthritis (Spondyloarthropathy), Synovial Sarcoma, Systemic Idiopathic Juvenile Arthritis, Takayasu Arteritis, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Uveitis.

The latest report Tyrosine Protein Kinase JAK1 - Pipeline Review, H2 2020, outlays comprehensive information on the Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)
  • The report reviews Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc
  • AstraZeneca Plc
  • Galapagos NV
  • Impetis Biosciences Ltd
  • Merck & Co Inc
  • Sareum Holdings Plc
  • MORE
Introduction

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Overview

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Therapeutics Development

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Therapeutics Assessment

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Companies Involved in Therapeutics Development

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Drug Profiles
  • Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Dormant Products
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Discontinued Products

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Product Development Milestones

Appendix

List of Tables
  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Indications, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products under Development by Companies, H2 2020 (Contd..1)
  • Products under Development by Companies, H2 2020
  • Number of Products under Investigation by Universities/Institutes, H2 2020
  • Products under Investigation by Universities/Institutes, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Pipeline by AbbVie Inc, H2 2020
  • Pipeline by Aclaris Therapeutics Inc, H2 2020
  • Pipeline by Alexion Pharmaceuticals Inc, H2 2020
  • Dormant Products, H2 2020
  • Dormant Products, H2 2020 (Contd..1), H2 2020
  • Dormant Products, H2 2020 (Contd..2), H2 2020
  • Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development by Stage of Development, H2 2020
  • Number of Products under Development by Therapy Areas, H2 2020
  • Number of Products under Development by Top 10 Indications, H2 2020
  • Number of Products by Mechanism of Actions, H2 2020
  • Number of Products by Stage and Mechanism of Actions, H2 2020
  • Number of Products by Top 10 Routes of Administration, H2 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2020
Note: Product cover images may vary from those shown
  • AbbVie Inc
  • Aclaris Therapeutics Inc
  • Alexion Pharmaceuticals Inc
  • Astellas Pharma Inc
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • Chipscreen Biosciences Ltd
  • Concert Pharmaceuticals Inc
  • Dizal (Jiangsu) Pharmaceutical Co Ltd
  • Eli Lilly and Co
  • Galapagos NV
  • Han Wha Pharma Co Ltd
  • Hangzhou East China Pharmaceutical Group Co Ltd
  • HK inno.N Corp
  • Impetis Biosciences Ltd
  • Incyte Corp
  • Japan Tobacco Inc
  • Jiangsu Carephar Pharmaceutical Co Ltd
  • Jiangsu Hengrui Medicine Co Ltd
  • Merck & Co Inc
  • Novartis AG
  • Pfizer Inc
  • Sareum Holdings Plc
  • Sierra Oncology Inc
  • Simcere Pharmaceutical Group
  • Theravance Biopharma Inc
  • Wuxi Fuxin Pharmaceutical Research and Development Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll